Tucatinib
Brand names: Tukysa · Active ingredient: Tucatinib
In short: Maintenance Treatment of HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. HER2-Positive Breast Can
What is Tucatinib used for?
Maintenance Treatment of HER2-Positive Breast Cancer
TUKYSA is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
HER2-Positive Breast Cancer
TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
âš Boxed warning (FDA's strongest warning)
•
TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge .
•
Obtain liver function tests before initiation and during treatment with TUKYSA. Withhold, reduce dose, or permanently discontinue TUKYSA as recommended based on severity of hepatotoxicity .
Tucatinib dosage
Select patients for treatment of unresectable or metastatic colorectal cancer with TUKYSA based on the presence of:
•HER2 overexpression or gene amplification . FDA-authorized tests for the detection of HER2 overexpression and gene amplification in patients with unresectable or metastatic colorectal cancer are not currently available, and
•RAS wild-type . Information on FDA-authorized tests for the detection of RAS mutations in patients with unresectable or metastatic colorectal cancer is available at http://www.fda.gov/CompanionDiagnostics.
The recommended dosages for TUKYSA are listed in Table 1.
Indication | Recommended TUKYSA Dosage | Duration of Therapy
Unresectable or Metastatic Breast Cancer
Maintenance Treatment of HER2‑Positive Breast Cancer | 300 mg orally twice daily in combination with trastuzumab and pertuzumab.
Refer to the Prescribing Information of combination agents for dosing and administration information. | Until disease progression or unacceptable toxicity.
Unresectable or Metastatic Breast Cancer
HER2-Positive Breast Cancer | 300 mg orally twice daily in combination with trastuzumab and capecitabine.
When given in combination with TUKYSA, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes after a meal. TUKYSA and capecitabine can be taken at the same time. | Until disease progression or unacceptable toxicity.
Unresectable or Metastatic Colorectal Cancer | 300 mg orally twice daily in combination with trastuzumab. | Until disease progression or unacceptable toxicity.
Administration Instructions
Advise patients to swallow TUKYSA tablets whole and not to chew, crush, or split prior to swallowing. Advise patients not to ingest a tablet if it is broken, cracked, or not otherwise intact.
Advise patients to take TUKYSA approximately 12 hours apart and at the same time each day with or without a meal .
If the patient vomits or misses a dose of TUKYSA, instruct the patient to take the next dose at its usual scheduled time.
The recommended TUKYSA dose reductions and dosage modifications for adverse reactions are provided in Tables 2 and 3. Refer to the Prescribing Information of combination agents for information about dosage modifications for these drugs.
Dose Reduction | Recommended TUKYSA Dosage
First | 250 mg orally twice daily
Second | 200 mg orally twice daily
Third | 150 mg orally twice daily
Permanently discontinue TUKYSA in patients unable to tolerate 150 mg orally twice daily.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal.
Adverse Reaction
Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03. …
How to take Tucatinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Hepatotoxicity
•Inform patients that TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge, and that they should report signs and symptoms of liver dysfunction to their healthcare provider immediately .
Diarrhea
•Inform patients that TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury and death. Instruct patients on how to manage diarrhea and to inform their healthcare provider immediately if there is any change in bowel patterns .
Embryo-Fetal Toxicity
•Inform pregnant women and females of reproductive potential of the risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy .
•Advise females of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose .
•Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose .
•Refer to the Prescribing Information of combination agents for pregnancy and contraception information. …
Warnings & precautions
Do not take this medicine if: None.
TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge .
Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 2 weeks for the first 2 months, then every 3 weeks during treatment, and as clinically indicated. For patients who experience AST/ALT >3 × ULN and bilirubin > ULN to ≤2 × ULN, repeat testing within 48-72 hours. For patients who experience AST/ALT >5 × ULN, withhold TUKYSA and repeat testing within 48-72 hours to determine if worsening. Based on the severity of hepatotoxicity, reduce dose or permanently discontinue TUKYSA . Institute weekly liver function monitoring if TUKYSA is resumed after resolution to Grade ≤1.
TUKYSA with trastuzumab and pertuzumab
In HER2CLIMB-05, 18% of patients who received TUKYSA had an ALT increase >5 × ULN, 10% had an AST increase >5 × ULN, and 1.2% had a bilirubin increase >3 × ULN (Grade ≥3). There were five confirmed Hy’s Law cases, including a fatal case. All occurred following rechallenge with TUKYSA. Hepatotoxicity led to dose reduction of TUKYSA in 16% of patients and discontinuation of TUKYSA in 8% of patients.
TUKYSA with trastuzumab and capecitabine
In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to dose reduction of TUKYSA in 8% of patients and discontinuation of TUKYSA in 1.5% of patients.
TUKYSA with trastuzumab
In MOUNTAINEER, 6% of patients had a bilirubin increase >3 × ULN (Grade ≥3), 6% had an AST increase >5 × ULN, and 4.7% had an ALT increase >5 × ULN. Hepatotoxicity led to dose reduction of TUKYSA in 3.5% of patients and discontinuation of TUKYSA in 2.3% of patients.
TUKYSA can cause severe diarrhea, including dehydration, hypotension, acute kidney injury, and death . …
Tucatinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•Hepatotoxicity
•Diarrhea
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Unresectable or Metastatic Breast Cancer
Maintenance Treatment of HER2-Positive Metastatic Breast Cancer (HER2CLIMB-05)
The safety of TUKYSA in combination with trastuzumab and pertuzumab was evaluated in HER2CLIMB-05 . Patients received TUKYSA 300 mg twice daily plus trastuzumab and pertuzumab (n = 326) or placebo plus trastuzumab and pertuzumab (n = 324). The median duration of treatment was 17 months (range: 0.4 to 37) for the TUKYSA arm.
Serious adverse reactions occurred in 17% of patients who received TUKYSA. Serious adverse reactions in ≥1% of patients included hepatotoxicity (3.9%). One patient experienced a fatal adverse reaction of drug-induced liver injury.
Permanent discontinuation of TUKYSA due to an adverse reaction occurred in 14% of patients. Adverse reactions leading to permanent discontinuation in ≥1% of patients were hepatotoxicity (8%) and diarrhea (1.5%).
Dosage interruptions of TUKYSA due to an adverse reaction occurred in 49% of patients. Adverse reactions which required dosage interruption in >5% of patients included hepatotoxicity (19%) and diarrhea (9%). …
Drug interactions
Table 10 summarizes the effect of other drugs on TUKYSA.
Strong CYP3A Inducers or Moderate CYP2C8 Inducers
Clinical Impact | Concomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations , which may reduce TUKYSA activity.
Management | Avoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer.
Strong or Moderate CYP2C8 Inhibitors
Clinical Impact | Concomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations , which may increase the risk of TUKYSA toxicity.
Management | Avoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor . Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
Table 11 summarizes the effect of TUKYSA on other drugs.
CYP3A Substrates
Clinical Impact | Concomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate , which may increase the toxicity associated with a CYP3A substrate.
Management | Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling. …
About this medicine
Tucatinib is a kinase inhibitor. The chemical name is (N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. The molecular formula is C26H24N8O2 and the molecular weight is 480.52 g/mol. The chemical structure is as follows:
TUKYSA (tucatinib) is supplied as 50 mg and 150 mg film-coated tablets for oral use and contain the following inactive ingredients:
Tablet core: copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.
Coating: yellow film coat: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated.
Each TUKYSA 50 mg tablet contains 10.10 mg (0.258 mEq) potassium and 9.21 mg (0.401 mEq) sodium.
Each TUKYSA 150 mg tablet contains 30.29 mg (0.775 mEq) potassium and 27.64 mg (1.202 mEq) sodium.
How it works: Tucatinib is a tyrosine kinase inhibitor of HER2. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f27eb1b9-b7fc-424e-988f-84dd7bb195a3. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate